Author

P. Casado-Izquierdo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:deep learning· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Rio-Machin· 2 shared J. Fitzgibbon· 2 shared P. Cutillas· 2 shared A. J. Finch· 1 shared A. M. Magee· 1 shared A. Parsons· 1 shared A. von Kriegsheim· 1 shared B. Pate· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Rio-Machin

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

V. Dembitz, H. Lawson, R. Burt, C. Philippe, S. C. James, S. Atkinson, J. Durko, L. M. Wang, J. Campos, A. M. Magee, K. Woodley, M. J. Austin, A. Rio-Machin, P. Casado-Izquierdo, F. Bewicke-Copley, , P. Gallipoli

SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.

bioRxiv · Aug 2, 2023Cancer Biology

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.

K. Davidson, P. Grevitt, M. Contreras, K. S. Bridge, M. Hermida, K. M. Shah, F. K. Mardakheh, M. Stubbs, P. A. Clarke, R. Burke, P. Casado-Izquierdo, P. R. Cutillas, S. A. Martin, T. V. Sharp

This paper identifies PF-477736 as a selective cytotoxic compound for LIMD1-deficient NSCLC cells and xenograft models, offering a potential targeted therapy for this understudied cancer subtype.

bioRxiv · Feb 1, 2021Cancer Biology

CKS1-dependent proteostatic regulation has dual roles combating acute myeloid leukemia whilst protecting normal hematopoiesis

W. Grey, A. Rio-Machin, P. Casado-Izquierdo, J. Miettinen, F. Copley, A. Parsons, C. Heckman, P. Cutillas, J. Gribben, J. Fitzgibbon, D. Bonnet

This study identifies CKS1-dependent proteostasis as a dual target for combating AML while protecting normal hematopoiesis through inhibition of SCFSKP2-CKS1.

bioRxiv · Dec 27, 2020 · PreprintCancer Biology